Halozyme Therapeutics Inc. has announced a proposed offering of $650 million aggregate principal amount of convertible senior notes due 2031 and $650 million aggregate principal amount of convertible senior notes due 2032. The company also expects to grant the initial purchasers a 13-day option to purchase up to an additional $100 million of the 2031 Notes and up to an additional $100 million of the 2032 Notes. The Convertible Notes will be offered to qualified institutional buyers under Rule 144A of the Securities Act of 1933. Halozyme plans to use a portion of the net proceeds to fund capped call transactions and to repurchase outstanding 0.25% convertible senior notes due 2027 and 1.00% convertible senior notes due 2028 through privately negotiated transactions. Specific pricing, maturity dates, and interest rates for the new notes were not disclosed in the document. No URL for the full prospectus is included in the document.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA16815) on November 05, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.